{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:16:19Z","timestamp":1791994579774,"version":"4.4.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.isci.2024.110721","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T12:47:40Z","timestamp":1723553260000},"page":"110721","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Stapokibart (CM310) targets IL-4R\u03b1 for the treatment of type 2 inflammation"],"prefix":"10.1016","volume":"27","author":[{"given":"Wei","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juntao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2024.110721_bib1","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41573-023-00750-1","article-title":"Type 2 chronic inflammatory diseases: targets, therapies and unmet needs","volume":"22","author":"Kolkhir","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.isci.2024.110721_bib2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/978-981-15-3449-2_4","article-title":"The Role of Genetics, the Environment, and Epigenetics in Atopic Dermatitis","volume":"1253","author":"Mu","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.isci.2024.110721_bib3","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2024.110721_bib4","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1111\/all.13209","article-title":"The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU","volume":"72","author":"Maurer","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.isci.2024.110721_bib5","doi-asserted-by":"crossref","first-page":"762","DOI":"10.2340\/00015555-3212","article-title":"Economic Burden of Adult Patients with Moderate to Severe Atopic Dermatitis Indicated for Systemic Treatment","volume":"99","author":"Ari\u00ebns","year":"2019","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.isci.2024.110721_bib6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2147\/JAA.S378505","article-title":"A Retrospective Claims Database Study to Clarify Disease Burden of Severe Asthma Patients with Type 2 High or Low Inflammation","volume":"16","author":"Harada","year":"2023","journal-title":"J.\u00a0Asthma Allergy"},{"key":"10.1016\/j.isci.2024.110721_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13555-016-0170-1","article-title":"Systemic Treatment of Adult Atopic Dermatitis: A Review","volume":"7","author":"Megna","year":"2017","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.isci.2024.110721_bib8","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.isci.2024.110721_bib9","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.jaad.2020.02.060","article-title":"Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS","volume":"82","author":"Silverberg","year":"2020","journal-title":"J.\u00a0Am. Acad. Dermatol."},{"key":"10.1016\/j.isci.2024.110721_bib10","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2024.110721_bib11","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41591-023-02320-9","article-title":"Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials","volume":"29","author":"Yosipovitch","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2024.110721_bib12","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMoa2205982","article-title":"Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis","volume":"387","author":"Dellon","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.isci.2024.110721_bib13","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2303951","article-title":"Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts","volume":"389","author":"Bhatt","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.isci.2024.110721_bib14","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/CM9.0000000000002747","article-title":"Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 2b trial","volume":"137","author":"Zhao","year":"2024","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.isci.2024.110721_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102076","article-title":"Efficacy and safety of CM310 in severe eosinophilic chronic rhinosinusitis with nasal polyps (CROWNS-1): a multicentre, randomised, double-blind, placebo-controlled phase 2 clinical trial","volume":"61","author":"Zhang","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.isci.2024.110721_bib16","article-title":"Efficacy and safety of stapokibart (CM310) in adults with moderate-to-severe atopic dermatitis: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial","volume":"190","author":"Zhao","year":"2024","journal-title":"J.\u00a0Am. Acad. Dermatol."},{"key":"10.1016\/j.isci.2024.110721_bib18","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.cell.2007.12.030","article-title":"Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4\/13 system","volume":"132","author":"LaPorte","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.isci.2024.110721_bib19","first-page":"126","article-title":"Long-term outcomes of different endoscopic sinus surgery in recurrent chronic rhinosinusitis with nasal polyps and asthma","volume":"58","author":"Zhang","year":"2020","journal-title":"Rhinology"},{"key":"10.1016\/j.isci.2024.110721_bib20","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cyto.2015.05.023","article-title":"Commentary: IL-4 and IL-13 receptors and signaling","volume":"75","author":"McCormick","year":"2015","journal-title":"Cytokine"},{"key":"10.1016\/j.isci.2024.110721_bib21","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.isci.2024.110721_bib22","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1002\/eji.200635972","article-title":"IL-4 induces expression of TARC\/CCL17 via two STAT6 binding sites","volume":"36","author":"Wirnsberger","year":"2006","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.isci.2024.110721_bib23","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s12026-011-8205-2","article-title":"Transcriptional regulation by STAT6","volume":"50","author":"Goenka","year":"2011","journal-title":"Immunol. Res."},{"key":"10.1016\/j.isci.2024.110721_bib24","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/all.14151","article-title":"Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation","volume":"75","author":"Le Floc'h","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.isci.2024.110721_bib25","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nrd822","article-title":"Preclinical safety evaluation of biotechnology-derived pharmaceuticals","volume":"1","author":"Cavagnaro","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.isci.2024.110721_bib26","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202216208","article-title":"A human monoclonal antibody bivalently binding two different epitopes in streptococcal M protein mediates immune function","volume":"15","author":"Bahnan","year":"2023","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.isci.2024.110721_bib27","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/bjd.20690","article-title":"The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study","volume":"186","author":"Zhao","year":"2022","journal-title":"Br. J. Dermatol."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004224019461?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004224019461?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T19:39:09Z","timestamp":1762630749000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004224019461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2589004224019461"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2024.110721","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stapokibart (CM310) targets IL-4R\u03b1 for the treatment of type 2 inflammation","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2024.110721","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110721"}}